至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

SMURF2 phosphorylation at Thr249 modifies glioma stemness and tumorigenicity by regulating TGF-β receptor stability

Commun Biol. 2022-01; 
Manami Hiraiwa, Kazuya Fukasawa, Takashi Iezaki, Hemragul Sabit, Tetsuhiro Horie, Kazuya Tokumura, Sayuki Iwahashi, Misato Murata, Masaki Kobayashi, Akane Suzuki, Gyujin Park, Katsuyuki Kaneda, Tomoki Todo, Atsushi Hirao, Mitsutoshi Nakada, Eiichi Hinoi
Products/Services Used Details Operation
Catalog Antibody anti-p-Smurf2Thr249 (#J1683BA260-5, 1:2000) (GenScript) Get A Quote

摘要

Glioma stem cells (GSCs) contribute to the pathogenesis of glioblastoma, the most malignant form of glioma. The implication and underlying mechanisms of SMAD specific E3 ubiquitin protein ligase 2 (SMURF2) on the GSC phenotypes remain unknown. We previously demonstrated that SMURF2 phosphorylation at Thr (SMURF2) activates its E3 ubiquitin ligase activity. Here, we demonstrate that SMURF2 phosphorylation plays an essential role in maintaining GSC stemness and tumorigenicity. SMURF2 silencing augmented the self-renewal potential and tumorigenicity of patient-derived GSCs. The SMURF2 phosphorylation level was low in human glioblastoma pathology specimens. Introduction of the SMURF2 mutant resulted in increased st... More

关键词